Numerous population pharmacokinetic studies on voriconazole have been conducted in
recent years. This review aimed to comprehensively summarize the population …

The objective of this study was to investigate the safety, tolembility, and pharmacokinetics of
oral voriconazole in subjects at high risk of developing fungal infections. This was a …

Voriconazole is a triazole antifungal agent with potent activity against a broad spectrum of
clinically significant pathogens. In vivo and in vitro studies have demonstrated that …

Voriconazole (VRCZ) is a triazole antifungal developed for the treatment of fungal infectious
disease and is available for both oral and intravenous administration. It has potent activity …

Aims Voriconazole is a new triazole antifungal agent with activity against a range of clinically
important and emerging pathogens. This study determined the effect of food on the …

Voriconazole is an effective antifungal drug, but adverse drug-drug interactions associated
with its use are of major clinical concern. To identify the mechanisms of these interactions …

Aims Voriconazole is a potent new triazole with broad‐spectrum antifungal activity against
clinically significant and emerging pathogens. The present study evaluated the safety …

Aims Voriconazole is a new triazole with broad‐spectrum antifungal activity against clinically
significant and emerging pathogens. These studies evaluated the pharmacokinetics and …

Pharmacokinetics A schematic representation of voriconazole disposition within the body is
provided in Fig. 1. Voriconazole is extensively metabolized, with less than 2% of the original …

Invasive fungal diseases are associated with significant morbidity and mortality in
immunocompromized patients. Voriconazole is the first line treatment of invasive …